Vanda's chief executive told Newsmax the company's drug could help with the nausea many GLP-1 users report. The claim comes from the company itself.
Recap by typeshit. Full story at Newsmax on MSN.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Mira Pharmaceuticals shared preclinical weight loss data for its candidate SKNY-1. The results come from mouse studies, not human trials.
Loading…